Clinical trial · Interventional
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
NCT00688116CI-TRIAL-00015641unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA 9090 (ganetespib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ganetespib
- interventionNames
- Drug: STA 9090 (ganetespib)
Primary outcomes (1)
- measure
- The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities and evaluation of Adverse Events in relation to Study Drug.
- timeFrame
- Cycle 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2. * Must have acceptable organ and marrow function per protocol parameters. * No clinically significant ventricular arrythmias or ischemia. Exclusion Criteria: * Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks.. * No previous radiation to \>25% of total bone marrow. * No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation. * No primary brain tumors or active brain metastases. * No use of any investigational agents within 4 weeks. * No treatment with chronic immunosuppressants. * No uncontrolled, intercurrent illness.
References
Publications (0)
Data not yet available
No reference posted for this study.